FDA’s Sentinel post-marketing surveillance system relies on what is known as "secondary use” of health records. That is, the system analyzes data created for one purpose (to process insurance claims) for a completely different reason (to answer research questions about outcomes of therapy, and especially adverse events).
The application of health claims data to regulatory purposes is, in fact, the key accomplishment of the Sentinel project to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?